HA
CTNM

HHLR Advisors’s Contineum Therapeutics CTNM Stock Holding History

HHLR Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Hold
669,337
– – 1.32% 14
2026
Q1 		$8.74M Hold
669,337
– – 0.52% 14
2025
Q4 		$7.65M Hold
669,337
– – 0.25% 16
2025
Q3 		$7.86M Hold
669,337
– – 0.19% 20
2025
Q2 		$2.66M Hold
669,337
– – 0.09% 26
2025
Q1 		$4.67M Hold
669,337
– – 0.13% 29
2024
Q4 		$9.81M Hold
669,337
– – 0.34% 18
2024
Q3 		$12.8M Hold
669,337
– – 0.28% 21
2024
Q2 		$11.8M Buy
+669,337
New +$10.8M 0.29% 27

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HHLR Advisors's CTNM Position: Q2 2026 in Review

HHLR Advisors held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 669,337 shares worth $11M. The position accounts for 1.32% of the portfolio, ranked #14.

HHLR Advisors first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. The position peaked at $12.8M in Q3 2024. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • HHLR Advisors held 669,337 shares of Contineum Therapeutics worth $11M as of Q2 2026.
  • HHLR Advisors left its Contineum Therapeutics share count unchanged in Q2 2026.
  • Contineum Therapeutics made up 1.32% of HHLR Advisors's portfolio in Q2 2026, its #14 holding.
  • HHLR Advisors first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • HHLR Advisors's Contineum Therapeutics position peaked at $12.8M in Q3 2024.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on HHLR Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.